Background: Progesterone (P) is thought to influence mood and affective states. Alterations of the inhibitory serotonin-1A (5-HT1A) receptor distribution are associated with depression and anxiety. This study evaluates the influence of plasma P levels on the 5-HT1A receptor binding in healthy male subjects. Methods: Molecular neuroimaging of the 5-HT1A receptor distribution using positron emission tomography and hormone assays for total plasma P and cortisol were done in a sample of 18 healthy men. Results: Plasma P levels explained up to 65% of the variability in 5-HT1A receptor binding in limbic regions including the amygdala, orbitofrontal cortex and retrosplenial cortex. When controlling for cortisol in the model, there was an expected decline in explained variances of 5-HT1A binding attributed to P. Conclusions: The results of this study provide further support for the effect of P on 5-HT1A receptor expression and raise the possibility that P mediates the vulnerability to mood disorders by affecting the serotonergic system.

Keywords:
Progesterone, Serotonin, Positron emission tomography, Cortisol
1.
Lanzenberger R, Wadsak W, Spindelegger C, Mitterhauser M, Akimova E, Mien LK, et al: Cortisol plasma levels in social anxiety disorder patients correlate with serotonin-1A receptor binding in limbic brain regions. Int J Neuropsychopharmacol 2010;13:1129–1143.
2.
Lanzenberger RR, Mitterhauser M, Spindelegger C, Wadsak W, Klein N, Mien LK, et al: Reduced serotonin-1A receptor binding in social anxiety disorder. Biol Psychiatry 2007;61:1081–1089.
3.
Parry BL: Perimenopausal depression. Am J Psychiatry 2008;165:23–27.
4.
Bethea CL, Lu NZ, Gundlah C, Streicher JM: Diverse actions of ovarian steroids in the serotonin neural system. Front Neuroendocrinol 2002;23:41–100.
5.
Rupprecht R, Reul JM, van Steensel B, Spengler D, Soder M, Berning B, et al: Pharmacological and functional characterization of human mineralocorticoid and glucocorticoid receptor ligands. Eur J Pharmacol 1993;247:145–154.
6.
Castren M, Patchev VK, Almeida OF, Holsboer F, Trapp T, Castren E: Regulation of rat mineralocorticoid receptor expression in neurons by progesterone. Endocrinology 1995;136:3800–3806.
7.
Ou XM, Storring JM, Kushwaha N, Albert PR: Heterodimerization of mineralocorticoid and glucocorticoid receptors at a novel negative response element of the 5-HT1A receptor gene. J Biol Chem 2001;276:14299–14307.
8.
Savitz J, Lucki I, Drevets WC: 5-HT1A receptor function in major depressive disorder. Prog Neurobiol 2009;88:17–31.
9.
Parsey RV, Ogden RT, Miller JM, Tin A, Hesselgrave N, Goldstein E, et al: Higher serotonin-1A binding in a second major depression cohort: modeling and reference region considerations. Biol Psychiatry 2010;68:170–178.
10.
Sarrieau A, Dussaillant M, Agid F, Philibert D, Agid Y, Rostene W: Autoradiographic localization of glucocorticosteroid and progesterone binding sites in the human post-mortem brain. J Steroid Biochem 1986;25:717–721.
11.
Brinton RD, Thompson RF, Foy MR, Baudry M, Wang J, Finch CE, et al: Progesterone receptors: form and function in brain. Front Neuroendocrinol 2008;29:313–339.
12.
Patel PD, Lopez JF, Lyons DM, Burke S, Wallace M, Schatzberg AF: Glucocorticoid and mineralocorticoid receptor mRNA expression in squirrel monkey brain. J Psychiatr Res 2000;34:383–392.
13.
Watzka M, Bidlingmaier F, Beyenburg S, Henke RT, Clusmann H, Elger CE, et al: Corticosteroid receptor mRNA expression in the brains of patients with epilepsy. Steroids 2000;65:895–901.
14.
Holsen LM, Spaeth SB, Lee JH, Ogden LA, Klibanski A, Whitfield-Gabrieli S, et al: Stress response circuitry hypoactivation related to hormonal dysfunction in women with major depression. J Affect Disord 2011;131:379–387.
15.
Van Wingen GA, van Broekhoven F, Verkes RJ, Petersson KM, Backstrom T, Buitelaar JK, et al: Progesterone selectively increases amygdala reactivity in women. Mol Psychiatry 2008;13:325–333.
16.
Vann SD, Aggleton JP, Maguire EA: What does the retrosplenial cortex do? Nat Rev Neurosci 2009;10:792–802.
17.
Vogt BA, Laureys S: Posterior cingulate, precuneal and retrosplenial cortices: cytology and components of the neural network correlates of consciousness. Prog Brain Res 2005;150:205–217.
18.
Diorio D, Viau V, Meaney MJ: The role of the medial prefrontal cortex (cingulate gyrus) in the regulation of hypothalamic-pituitary-adrenal responses to stress. J Neurosci 1993;13:3839–3847.
19.
Moses-Kolko EL, Wisner KL, Price JC, Berga SL, Drevets WC, Hanusa BH, et al: Serotonin-1A receptor reductions in postpartum depression: a positron emission tomography study. Fertil Steril 2008;89:685–692.
20.
Jovanovic H, Cerin A, Karlsson P, Lundberg J, Halldin C, Nordstrom AL: A PET study of 5-HT1A receptors at different phases of the menstrual cycle in women with premenstrual dysphoria. Psychiatry Res 2006;148:185–193.
21.
Halbreich U: Major depression is not a diagnosis, it is a departure point to differential diagnosis – clinical and hormonal considerations (a commentary and elaboration on Antonejevic’s paper). Psychoneuroendocrinology 2006;31:16–24.
22.
Andreen L, Nyberg S, Turkmen S, van Wingen G, Fernandez G, Backstrom T: Sex steroid-induced negative mood may be explained by the paradoxical effect mediated by GABAA modulators. Psychoneuroendocrinology 2009;34:1121–1132.
23.
Bieglmayer C, Chan DW, Sokoll L, Imdahl R, Kobayashi M, Yamada E, et al: Multicentre performance evaluation of the E170 module for modular analytics. Clin Chem Lab Med 2004;42:1186–1202.
© 2011 S. Karger AG, Basel
2011
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.